Recent advances in the development of new treatments for celiac disease.
Study Goal
The researchers aimed to evaluate the necessity and potential alternatives to a lifelong gluten-free diet for managing celiac disease.
Results Summary
The study found that a strict gluten-free diet effectively reverses small intestinal histological changes and alleviates symptoms in celiac disease patients, but it is restrictive and nutritionally suboptimal. Several non-dietary treatment options are under development to complement or replace the gluten-free diet.
Population
Individuals with celiac disease (genetically susceptible to gluten-induced autoimmune reactions).
Effective Dosage
Not specified
Duration
Lifelong (implied by the nature of the gluten-free diet requirement)
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
lifelong strict gluten-free diet | decrease | small intestinal histological changes and symptoms | genetically susceptible individuals with celiac disease | - | recover and disappear | #1 |
degradation of gluten intraluminally | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #2 |
reduction of mucosal permeability | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #3 |
inhibition of the transglutaminase 2 enzyme | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #4 |
blocking antigen presentation by HLA-DQ2 or HLA-DQ8 | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #5 |
modulation of the immune responses of many cytokines | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #6 |
vaccination | decrease | gluten-induced small intestinal mucosal injury | patients with celiac disease | - | suggested as possible drug target | #7 |
INTRODUCTION: Celiac disease is a common autoimmune condition induced by dietary gluten in genetically susceptible individuals. So far, the only available treatment for the disorder is a lifelong strict gluten-free diet, because of which small intestinal histological changes recover and symptoms disappear. However, gluten-free dieting is restrictive, and nutritionally less than optimal, and gluten is difficult to avoid. AREAS COVERED: With improving insight into the pathogenesis of celiac disease, several possible drug targets have been suggested. The new strategies include degradation of gluten intraluminally, reduction of mucosal permeability, inhibition of the transglutaminase 2 enzyme, blocking antigen presentation by HLA-DQ2 or HLA-DQ8, modulation of the immune responses of many cytokines, and vaccination. EXPERT OPINION: Non-dietary treatment options are warranted either as adjunctive therapy together with dieting or to replace the gluten-free diet. The key question is whether the envisaged novel drug is able to prevent gluten-induced small intestinal mucosal injury as efficiently as a strict gluten-free diet, alleviating symptoms and signs of the disease. Furthermore, the gluten dose that can be detoxified, if at all, must be established. The new drug should also be as safe as dietary treatment. Several novel treatment options are under development.